Custom service
Mammalian Cell based VLP Production
Particles assembled with the glycosylation and processing of a human cell.
Some particles only assemble correctly in a mammalian cell. Envelope glycoproteins that require complex N-glycans, furin cleavage and correct trafficking; capsids whose assembly depends on mammalian chaperones; particles intended for clinical or regulatory contexts where the production system is part of the specification. For these, mammalian cell VLP production is not a preference — it is the requirement.
HEK293 is the default host for transient production, giving particles within two to three weeks of transfection and full control over the glycoform through cell line choice and medium. CHO is used where a production cell line is the eventual goal. Expression vectors are built with the structural proteins under independent promoters or separated by 2A peptides, and the ratio of components — which determines how many copies of each protein the particle carries — is tuned at the plasmid level.
QC carries more weight here than in other systems, because mammalian processing adds variables. Glycosylation is profiled, proteolytic processing is verified by mass spectrometry, and particle morphology and count are confirmed by electron microscopy. Where the particle is intended as an immunogen or calibrator, antigenicity is measured on the final batch.
Mammalian VLP production is chosen when particle assembly or antigenicity depends on mammalian processing, when the particle carries a clinically relevant glycoform, and when regulatory context demands a mammalian production system.
It yields less per litre than insect cells and costs more per batch. When the particle assembles fine in insect cells and the glycan difference does not matter, the insect system is the better economic choice.
Batches are released with TEM particle count and morphology, protein composition, glycan profile, processing verification by mass spectrometry, antigenicity where a readout exists, and endotoxin. Component ratio in the released particle is measured, not assumed from the transfection mix.
Service Highlights
- Native processing. Complex N-glycans, furin cleavage and correct trafficking, so envelope proteins assemble in their mature form.
- Component ratio control. Promoter and 2A-peptide design tuned at the plasmid level to set the copy number of each structural protein.
- Transient or stable. HEK293 transient for speed; CHO stable pools for repeated production under a documented process.
- Glycoform control. Cell line, medium and glycosidase treatments used to adjust the glycan profile where it matters.
- Processing verification. Cleavage and maturation confirmed by mass spectrometry, not inferred from size on a gel.
- Regulatory-compatible. Production under serum-free defined conditions, suitable for programmes heading toward submission.
How the work runs
Particle and vector design
Structural proteins, promoters and 2A linkers arranged to control component ratios; glycosylation requirements reviewed.
Transient expression
HEK293 transfection at the optimised plasmid ratios, harvested at peak particle yield.
Optional stable pool
CHO stable pool generation for programmes requiring repeated production.
Purification
Clarification, concentration and particle-based purification by SEC or chromatography.
Characterisation
TEM morphology and count, protein composition, glycan profiling, processing verification by LC-MS.
Antigenicity and release
Conformational antibody or ligand binding on the final particle, with a batch certificate.
Specifications & timeline
- Hosts
- HEK293 transient, CHO stable pool
- VLP types
- Enveloped particles with mammalian glycoproteins; custom assemblies
- Scale
- 0.5–10 L culture
- QC
- TEM, SDS-PAGE, LC-MS processing check, glycan profile, antigenicity, endotoxin
- Timeline
- 6–12 weeks per construct
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.